Spire Wealth Management lessened its holdings in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 23.1% during the 4th quarter, according to its most recent filing with the Securities & Exchange ...

Edwards Lifesciences Corp. closed 26.14% below its 52-week high of $96.12, which the company reached on March 28th.

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when DexCom (DXCM) reports results for the quarter ended December 2024. While this widely-known consensus outlook ...

In its upcoming report, Edwards Lifesciences (EW) is predicted by Wall Street analysts to post quarterly earnings of $0.55 per share, reflecting a decline of 14.1% compared to the same period last ...